不同类型酪氨酸激酶抑制剂对老年非小细胞肺癌表皮生长因子受体不同突变患者疗效对比

Comparison of therapeutic effects of different types of tyrosine kinase inhibitors on elderly patients with different mutations of epidermal growth factor receptor in non-small cell lung cancer

中文关键词: 老年  非小细胞肺癌  酪氨酸激酶抑制剂  表皮生长因子受体  基因突变

英文关键词: elderly  non-small cell lung carcinoma  tyrosine kinase inhibitor  epidermal growth factor receptor  gene mutation

中文摘要:

      目的 比较不同类型酪氨酸激酶抑制剂(TKIs)对老年晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)常见突变和少见突变的治疗效果.方法 回顾性分析2021年5月—2023年12月邯郸市中心医院接受不同种类EGFR-TKIs治疗的老年晚期NSCLC患者资料.比较常见突变组和少见突变组患者客观缓解率(ORR)、疾病控制率(DCR)和无进展生存期(PFS).结果 123例老年晚期NSCLC患者中常见突变87例(70.73％),少见突变36例(29.27％).与常见突变组相比,少见突变组O RR(55.17％vs 30.55％)及DCR(89.65％vs 72.22％)构成比较少(P＜0.05),中位PFS较短(16.0个月vs9.0个月,P＜0.001).二代EGFR-TKIs对少见突变患者治疗效果最佳(P＜0.001),一代与三代EGFR-TKIs对少见突变患者的疗效无差异(P＞0.05).结论 EGFR-TKIs治疗对老年晚期NSCLC突变患者具有一定疗效,二代EGFR-TKIs可能作为少见突变患者的首选治疗方案.

英文摘要:

      Objective To compare the therapeutic effects of different types of tyrosine kinase inhibitors(TKIs)on common and rare mutations of epidermal growth factor receptor(EGFR)in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods The clinical data from elderly patients with advanced NSCLC treated with different kinds of EG-FR-TKIs in Central Hospital of Handan City between May 2021 and December 2023 were retrospectively analyzed.The objective response rate(ORR),disease control rate(DCR),and progression-free survival(PFS)were compared between the common mutation group and the rare mutation group.Results Among the 123 elderly patients with advanced NSCLC,87(70.73％)had common EGFR mutations and 36(29.27％)had rare mutations.Compared with the common mutation group,the rare muta-tion group had significantly lower ORR(55.17％vs 30.55％)and DCR(89.65％vs72.22％)(P＜0.05).The median PFS in the rare mutation group was significantly shorter than that in the common mutation group(16.0 months vs 9.0 months,P＜0.001).Second-generation EGFR-TKIs demonstrated the best therapeutic effect on patients with rare mutations(P＜0.001),while the difference in therapeutic effect between the first-generation and third-generation EGFR-TKIs on patients with rare mu-tations was no significant(P＞0.05).Conclusion EGFR-TKIs therapy has a certain therapeutic effect on elderly patients with advanced NSCLC mutations,and second-generation EGFR-TKIs may be used as the preferred treatment option for rare mutation patients.